Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Other Accumulated Expenses: 2012-2025

Historic Other Accumulated Expenses for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Sep 2025 value amounting to $842,000.

  • Catalyst Pharmaceuticals' Other Accumulated Expenses rose 87.53% to $842,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $842,000, marking a year-over-year increase of 87.53%. This contributed to the annual value of $417,000 for FY2024, which is 10.32% down from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $842,000 for Q3 2025, which was up 12.72% from $747,000 recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Other Accumulated Expenses registered a high of $2.2 million during Q1 2025, and its lowest value of $372,000 during Q2 2024.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Other Accumulated Expenses value was $465,000 (recorded in 2023), while the average stood at $788,143.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first fell by 10.32% in 2024, then spiked by 100.81% in 2025.
  • Catalyst Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $465,000 in 2023, then dropped by 10.32% to $417,000 in 2024, then skyrocketed by 87.53% to $842,000 in 2025.
  • Its Other Accumulated Expenses was $842,000 in Q3 2025, compared to $747,000 in Q2 2025 and $2.2 million in Q1 2025.